Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL RPC1063 AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATE TO SEVERE ULCERATIVE COLITIS

Intervention/treatment:
OZANIMOD (RPC1063)
Medical condition:
ULCERATIVE COLITIS
Protocol code:
RPC01-3101
Control number:
184226
Status:
Closed
Approved:
May 28, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02435992
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Bristol-Myers Squibb Study Director
Organization
Bristol-Myers Squibb
Phone:
Please Email
Sponsor
CELGENE INTERNATIONAL II SARL (CIS II)

Locations

British Columbia

Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9

Manitoba

Brandon Medical Arts Clinic
Brandon, Manitoba, R7A 0N7

Ontario

Humber River Hospital
Toronto, Ontario, M3M 0B2
LHSC - University Hospital
London, Ontario, N6A 5A5
LHSC - Victoria Hospital
London, Ontario, N6A 5W9
Mount Sinai Hospital
Toronto, Ontario, M5T 3L9
Toronto Digestive Disease Associates, Inc.
Vaughan, Ontario, L4L 4Y7
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
Viable Clinical Research - Lindsay
Lindsay, Ontario, K9V 5G6

Quebec

Centre integre de sante et de services sociaux de la Monteregie-Centre - Hopital Charles-Le Moyne
Greenfield Park, Quebec, J4V 2H1
CHUS - Hôpital Fleurimont
Sherbrooke, Quebec, J1H5N4
The Ottawa Hospital - General Campus
Ottawa, Quebec, K1H 8L6

Results

See the results from the trial NCT02435992. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?